APOL1 and focal segmental glomerulosclerosis: Those who agreed that the benefits outweigh the risks were also more likely to agree that the presence of two APOL1 risk alleles in one of their Focal Segmental Glomerulosclerosis (FSGS) patients would affect their therapeutic management (Q8, p = 0.006) and were more likely to agree that they would comply with the dosing suggestions of a pharmacogenomic test for new prescriptions (Q22, p = 0.002).